Table 2 Relative and absolute excess risks for any first hospitalization and first hospitalization in 12 main diagnostic groups and selected disease categories distinguished by absolute excess risk ≥3.

From: Multisystem burden of neurofibromatosis 1 in Denmark: registry- and population-based rates of hospitalizations over the life span

 

Number of hospitalizations (NF1)

Number of expected hospitalizations

RR

95% CI

AERa

95% CI

% of total AER (n/N)

Any first hospitalization

All

1716

730.9

2.3

2.2–2.5

543

499–586

 

Females

872

391.7

2.2

2.1–2.4

518

458–579

 

Males

844

340.3

2.5

2.3–2.7

567

505–629

 

Age at end of follow-up (years)

 0–9

312

80.1

3.9

3.5–4.4

878

753–1002

 

 10–14

109

28.5

3.8

3.1–4.7

433

325–541

 

 15–19

96

38.5

2.5

2.0–3.1

330

221–439

 

 20–29

149

78.9

1.9

1.6–2.2

235

155–315

 

 30–39

202

87.2

2.3

2.0–2.7

395

300–489

 

 40–49

243

95.2

2.6

2.2–2.9

569

456–683

 

 50–59

252

89.1

2.8

2.5–3.2

908

746–1071

 

 ≥60

353

148.5

2.4

2.2–2.6

1258

1055–1460

 

First hospitalization in specific disease category

Infectious and parasitic diseases

262

127.5

2.0

1.8–2.3

37

28–46

6.7 (37/552)

 Intestinal infectious diseases

103

40.2

2.6

2.1–3.2

17

11–22

 

 Sepsis

76

34.3

2.2

1.7–2.8

11

6–15

 

 Infectious hepatitis, HIV, and other viral diseases

39

21.8

1.8

1.3–2.5

5

1–8

 

Malignant neoplasm

457

192.1

2.4

2.1–2.6

74

62–86

13.4 (74/552)

 Eye, brain and other parts of CNS

151

8.3

18.1

13.9–23.8

39

32–45

 

 Mesothelium and connective tissue

75

1.7

44.2

25.7–75.7

19

15–24

 

 Breast

49

30.1

1.6

1.2–2.2

5

1–9

 

 Digestive organs

62

45.7

1.4

1.04–1.8

4

0–8

 

Benign neoplasms

322

61.6

5.2

4.6–6.0

75

65–86

13.6 (75/552)

 Peripheral and autonomic nervous system

76

0.2

365

90–1486

20

16–25

 

 Skin

37

3.8

9.7

6.1–15.3

9

6–12

 

 Female genital organs

59

26.0

2.3

1.7–3.0

9

5–13

 

 Muscular and connective tissue

32

1.8

17.7

9.9–31.9

8

5–11

 

 Digestive organs

38

10.5

3.6

2.5–5.3

7

4–10

 

 Respiratory system

26

3.6

7.2

4.3–12.0

6

3–8

 

 Lipoma

22

4.7

4.7

2.8–7.8

5

2–7

 

 Hemangioma and lymphangioma

13

1.3

10.2

4.6–22.3

3

1–5

 

 Endocrine organs

15

1.9

7.8

3.9–15.5

3

1–5

 

Endocrine diseases, nutritional deficiencies and other metabolic diseases

230

135.9

1.7

1.5–1.9

26

17–34

4.7 (26/552)

 Diseases of endocrine glands (except thyroid and pituitary gland)

41

5.5

7.4

4.9–11.2

9

6–13

 

 Abnormal menstruation

52

36.1

1.4

1.1–1.9

4

0–8

 

 Diseases of pituitary gland

18

1.2

15.4

7.3–32.5

4

2–7

 

 Diseases of the thyroid gland

28

16.0

1.8

1.2–2.6

3

0–6

 

Diseases of blood and blood forming organs

84

44.0

1.9

1.5–2.4

11

6–15

2.0 (11/552)

 Anemia

65

34.6

1.9

1.4–2.5

8

4–12

 

Diseases of nervous system and sense organs

403

128.7

3.1

2.8–3.5

80

68–91

14.5 (80/552)

 Diseases of nerves and peripheral ganglia

143

32.1

4.5

3.7–5.4

30

24–36

 

 Epilepsy

99

18.0

5.5

4.3–7.0

22

16–27

 

 Inflammatory and other conditions of the eye

76

20.8

3.7

2.8–4.8

15

10–19

 

 Inflammatory diseases of ear

33

16.1

2.0

1.4–3.0

4

1–7

 

 Migraine and headache

25

13.3

1.9

1.2–2.9

3

0–6

 

Diseases of circulatory system

452

328.8

1.4

1.2–1.5

35

23–47

6.3 (35/552)

 Cerebrovascular disease

149

94.7

1.6

1.3–1.9

14

8–21

 

 Venous and lymphatic disease

89

54.2

1.6

1.3–2.1

9

4–14

 

 Hypertensive disorders (except renal vascular hypertension)

44

29.7

1.5

1.1–2.0

4

0–7

 

 Diseases of arteries, arterioles and capillaries

49

35.8

1.4

1.02–1.9

3

0–7

 

Diseases of respiratory system

454

256.3

1.8

1.6–2.0

57

45–69

10.3 (57/552)

 Pneumonia

196

111.2

1.8

1.5–2.1

23

15–30

 

 Hypertrophy of tonsils and adenoids

60

29.1

2.1

1.6–2.7

8

4–12

 

 Acute upper respiratory infections

63

31.8

2.0

1.5–2.6

8

4–13

 

 Respiratory failure

57

25.9

2.2

1.7–2.9

8

4–12

 

 Bronchitis and emphysema

82

60.0

1.4

1.1–1.7

6

1–11

 

 Asthma

39

22.5

1.7

1.2–2.4

4

1–8

 

Diseases of digestive organs

497

301.2

1.7

1.5–1.8

58

45–71

10.5 (58/552)

 Hernia of abdominal cavity

97

58.9

1.7

1.3–2.0

10

5–16

 

 Diseases of the teeth and supporting structures

48

11.3

4.3

3.0–6.0

10

6–13

 

 Constipation

60

23.6

2.5

1.9–3.4

10

5–14

 

 Peptic ulcer

57

31.9

1.8

1.4–2.4

7

3–11

 

 Diseases of anal and rectal regions

56

30.6

1.8

1.4–2.4

7

3–11

 

 Paralytic ileus and intestinal obstruction

41

16.9

2.4

1.7–3.4

6

3–10

 

 Noninfective enteritis and colitis

36

20.5

1.8

1.2–2.5

4

1–7

 

 Diseases of esophagus

28

14.9

1.9

1.3–2.8

3

1–6

 

Diseases of urinary system and genital organs

329

207.3

1.6

1.4–1.8

34

24–44

6.2 (34/52)

 Infections of urinary system

107

58.2

1.8

1.5–2.3

13

7–18

 

 Diseases of prostate

39

22.7

1.7

1.2–2.4

4

1–8

 

 Urolithiasis

37

20.5

1.8

1.3–2.6

4

1–8

 

Diseases of skin and subcutaneous tissue

139

69.2

2.0

1.7–2.4

19

12–25

3.4 (19/552)

 Infections of skin and subcutaneous tissue

75

45.1

1.7

1.3–2.1

8

3–13

 

 Other inflammatory conditions of skin and subcutaneous tissue

29

14.9

1.9

1.3–2.9

4

1–7

 

Diseases of bones, joints and soft tissue

371

212.5

1.7

1.6–1.9

46

35–57

8.3 (46/552)

 Osteomyelitis and other diseases of bones and joints

187

108.8

1.7

1.5–2.0

21

14–29

 

 Scoliosis

51

1.5

34.8

19.2–62.8

13

9–17

 
  1. A complete list of all subgroups and diagnoses is seen in Supplemental Table S2.
  2. AER absolute excess risk, CI confidence interval, CNS central nervous system, NF1 neurofibromatosis 1, RR relative risk.
  3. aAER per 10,000 person-years.